Literature DB >> 23842126

Discrepant coagulation profile in HIV infection: elevated D-dimer but impaired platelet aggregation and clot initiation.

Anna K Haugaard1, Tamara T Lund, Carsten Birch, Frederikke Rönsholt, Marius Trøseid, Henrik Ullum, Jan Gerstoft, Per I Johansson, Susanne D Nielsen, Sisse R Ostrowski.   

Abstract

OBJECTIVES: In HIV infection, cardiovascular disease (CVD) has emerged as a clinical problem, and elevated D-dimer has been reported. The pathophysiologic mechanisms underlying this remain unclear. We aimed to investigate whether untreated HIV-infected individuals display evidence of functional coagulopathy and whether this was associated with microbial translocation.
DESIGN: The study population consisted of 50 HIV-infected untreated individuals and 50 HIV-infected individuals on combination antiretroviral therapy (cART). Groups were matched for age, sex and current CD4cell count.
METHODS: Coagulation analyses included D-dimer and the functional haemostatic whole blood tests, thromboelastography (TEG) and platelet aggregation (Multiplate, impedance aggregometry). Microbial translocation was assessed by plasma levels of lipopolysaccharide (LPS).
RESULTS: A larger proportion of untreated individuals compared with treated individuals had D-dimer above normal reference range (27.7 vs. 2.2%, P = 0.001). In both treated and untreated individuals, delayed clot initiation with TEG R-time above upper reference range (18 and 28%, respectively, both P < 0.001) and TEG angle below lower reference range [14% (P = 0.004) and 24% (P < 0.001), respectively] was found. In untreated individuals, 64.6% had aggregation response below threshold in at least two of four tests compared with 36.7% in treated individuals (P = 0.010). Untreated individuals with increased D-dimer levels were relatively hypercoagulable by thromboelastography. Furthermore, in untreated patients, a negative association between microbial translocation and platelet aggregation was found.
CONCLUSION: Elevated D-dimer in untreated HIV-infected individuals was confirmed. However, in both untreated and treated individuals, reduced platelet aggregation and clot initiation was found. The impact of reduced platelet function in HIV infection and a potential role of microbial translocation warrant further investigation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23842126     DOI: 10.1097/01.aids.0000432462.21723.ed

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  13 in total

1.  Coagulation and morbidity in treated HIV infection.

Authors:  Nicholas T Funderburg; Michael M Lederman
Journal:  Thromb Res       Date:  2014-05       Impact factor: 3.944

Review 2.  Microbial translocation and cardiometabolic risk factors in HIV infection.

Authors:  Marius Trøseid; Ingjerd W Manner; Karin K Pedersen; Judith M Haissman; Dag Kvale; Susanne D Nielsen
Journal:  AIDS Res Hum Retroviruses       Date:  2014-03-25       Impact factor: 2.205

3.  Coagulation imbalance and neurocognitive functioning in older HIV-positive adults on suppressive antiretroviral therapy.

Authors:  Jessica L Montoya; Jennifer Iudicello; Hannah A Oppenheim; Pariya L Fazeli; Michael Potter; Qing Ma; Paul J Mills; Ronald J Ellis; Igor Grant; Scott L Letendre; David J Moore
Journal:  AIDS       Date:  2017-03-27       Impact factor: 4.177

4.  Altered Intestinal Permeability and Fungal Translocation in Ugandan Children With Human Immunodeficiency Virus.

Authors:  Sahera Dirajlal-Fargo; Vanessa El-Kamari; Lukasz Weiner; Lingpeng Shan; Abdus Sattar; Manjusha Kulkarni; Nicholas Funderburg; Rashidah Nazzinda; Christine Karungi; Cissy Kityo; Victor Musiime; Grace A McComsey
Journal:  Clin Infect Dis       Date:  2020-05-23       Impact factor: 9.079

Review 5.  Chronic HIV disease and activation of the coagulation system.

Authors:  Jason V Baker
Journal:  Thromb Res       Date:  2013-08-29       Impact factor: 3.944

Review 6.  Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients.

Authors:  Nicholas T Funderburg
Journal:  Curr Opin HIV AIDS       Date:  2014-01       Impact factor: 4.283

7.  Thromboelastography on plasma reveals delayed clot formation and accelerated clot lyses in HIV-1 infected persons compared with healthy controls.

Authors:  Frederikke Falkencrone Rönsholt; Jan Gerstoft; Henrik Ullum; Pär Ingemar Johansson; Terese Lea Katzenstein; Sisse Rye Ostrowski
Journal:  BMC Infect Dis       Date:  2015-09-24       Impact factor: 3.090

8.  Impact of HIV infection on the presentation, outcome and host response in patients admitted to the intensive care unit with sepsis; a case control study.

Authors:  Maryse A Wiewel; Michaëla A Huson; Lonneke A van Vught; Arie J Hoogendijk; Peter M C Klein Klouwenberg; Janneke Horn; René Lutter; Olaf L Cremer; Marcus J Schultz; Marc J Bonten; Tom van der Poll
Journal:  Crit Care       Date:  2016-10-10       Impact factor: 9.097

9.  Microbiota-dependent metabolite and cardiovascular disease marker trimethylamine-N-oxide (TMAO) is associated with monocyte activation but not platelet function in untreated HIV infection.

Authors:  Judith M Haissman; Anna K Haugaard; Sisse R Ostrowski; Rolf K Berge; Johannes R Hov; Marius Trøseid; Susanne D Nielsen
Journal:  BMC Infect Dis       Date:  2017-06-23       Impact factor: 3.090

10.  Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.

Authors:  Caroline A Sabin; Peter Reiss; Lene Ryom; Andrew N Phillips; Rainer Weber; Matthew Law; Eric Fontas; Amanda Mocroft; Stephane de Wit; Colette Smith; Francois Dabis; Antonella d'Arminio Monforte; Wafaa El-Sadr; Jens D Lundgren
Journal:  BMC Med       Date:  2016-03-31       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.